1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Terns’ Early Data May Position It Well In GLP-1 Obesity Race

 
• By Joseph Haas

In a multiple-ascending dose Phase I trial, Terns’ oral GLP-1 agonist showed 4.9% placebo-adjusted weight loss at 28 weeks, with no severe gastrointestinal side effects.

obesity medication with tape measure
Terns looks competitive in the obesity GLP-1 agonist competition with Phase I data • Source: Shutterstock

The obesity space may have another serious entry as Terns Pharmaceuticals, Inc. unveiled Phase I data for its oral, daily GLP-1 agonist TERN-601 on 9 September that indicate competitive weight-loss performance at 28 days with a clean safety and tolerability profile. Terns is working to move TERN-601 quickly into Phase II in 2025.

Key Takeaways

  • Terns reported 4.9% placebo-adjusted weight loss at 28 weeks in a Phase I study of oral GLP-1 agonist TERN-601.

  • With a clean tolerability and...

In a single and multiple-ascending dose trial design, Terns reported an absolute 5.5% reduction in weight from baseline with the highest dose tested, 740mg daily, as well as a placebo-adjusted...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

More from R&D

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.